Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: A Nordic nested case-control study

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 12, 2005, Pages 2952-2955

  Korodi, Zoltan ^a   Dillner, Joakim ^a   Jellum, Egil ^b   Lumme, Sonja ^d   Hallmans, Göran ^f   Thoresen, Steinar ^c   Hakulinen, Timo ^e   Stattin, Pär ^f   Luostarinen, Tapio ^e   Lehtinen, Matti ^g   Hakama, Matti ^g  

^a LUND UNIVERSITY   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d Helsinki Heart Study   (Finland)

^e FINNISH CANCER REGISTRY   (Finland)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CASE CONTROL STUDY; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FINLAND; FOLLOW UP; GENE IDENTIFICATION; GENETIC LINKAGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NORWAY; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SERODIAGNOSIS; SEROPREVALENCE; SWEDEN;

ADULT; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROSTATIC NEOPLASMS; REGISTRIES; RISK FACTORS; SCANDINAVIA; SEROEPIDEMIOLOGIC STUDIES;

EID: 30344433469     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0602     Document Type: Article

References (33)

1. Strickler HD, Goedert JJ. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001;23:144-51.
2. Andersson SO, Baron J, Bergstrom R, et al. Lifestyle factors and prostate cancer risk: a case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1996;5:509-13.
3. Dillner J, Knekt P, Boman J, et al. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 1998;75:564-7.
4. Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J. Prostate cancer risk and serologic evidence of human papillomavirus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2003;12:872-5.
5. Rosenblatt KA, Wicklund KG, Stanford JL. Sexual factors and the risk of prostate cancer. Am J Epidemiol 2001;153:1152-8.
6. Taylor ML, Mainous AG, III, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005;37:506-12.
7. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
8. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31:14-9.
9. Weijerman PC, van Drunen E, Konig JJ, et al. Specific cytogenetic aberrations in two novel human prostaric cell lines immortalized by human papillomavirus type 18 DNA. Cancer Genet Cytogenet 1997;99:108-15.
10. Terris MK, Peehl DM. Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology 1997;50:150-6.
11. Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral Infections. Prostate 2002;53:263-76.
12. Noda T, Sasagawa T, Dong Y, et al. Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urol Res 1998; 26:165-9,
13. Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U. Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 1999;59:823-5.
14. Carozzi F, Lombardi FC, Zendron P, et al. Association of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsies. Int J Biol Markers 2004;19:257-61.
15. Effert PJ, Frye RA, Neubauer A, Liu ET, Walther PJ. Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction. J Urol 1992;147:192-6.
16. Strickler HD, Burk R, Shah K, et al. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998;82:1118-25.
17. Rosenblatt KA, Carter JJ, Iwasaki LM, Galloway DA, Stanford JL. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:763-8.
18. Hayes RB, Pottern LM, Strickler H, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000;82:718-25.
19. Hisada M, Rabkin CS, Strickler HD, et al. Human papillomavirus antibody and risk of prostate cancer. JAMA 2000;283:340-1.
20. Strickler HD, Schiffman MH, Shah KV, et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev 1998;7:305-13.
21. Stattin P, Adlercreutz H, Tenkanen L, et al. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer 2002;99: 124-9.
22. Schroder FH, Hermanek P, Denis L, et al. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
23. Kirnbauer R, Hubbert NL, Wheeler CM, et al. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-9.
24. Dillner J, Wiklund F, Lenner P, et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 1995;60: 377-82.
25. Heino P, Eklund C, Fredriksson-Shanazarian V, et al. Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst 1995;87: 437-40.
26. Andersson-Ellstrom A, Dillner J, Hagmar B, et al. Comparison of development of serum antibodies to HPV-16 and HPV-33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996;23:234-8.
27. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172: 1425-30.
28. Suzuki H, Komiya A, Aida S, et al. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Prostate 1996;28: 318-24.
29. Saad F, Gu K, Jean-Baptiste J, Gauthier J, MesMasson AM. Absence of human papillomavirus sequences in early stage prostate cancer. Can J Urol 1999;6:834-8.
30. Masood S, Rhatigan RM, Powell S, Thompson J, Rodenroth N. Human papillomavirus in prostatic cancer: no evidence found by in situ DNA hybridization. South Med J 1991;84:235-6.
31. Konya J, Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 2001;82:205-38.
32. Lagergren J, Wang Z, Bergstrom R, Dillner J, Nyren O. Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst 1999;91: 156-62.
33. Anttila T, Tenkanen L, Lumme S, et al. Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2005;14:385-9.